An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma.

Trial Profile

An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Cisplatin; Vandetanib
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 05 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 05 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 05 Jul 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top